PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.

Abstract Risk grouping for treatment and follow-up strategy of early stage endometrial cancer is confusing to apply in clinical conditions. We investigated the stage-based prognostic factors for tumor recurrence in stage I endometrial cancer with endometrioid histology (EEC).The medical records of women diagnosed with endometrial adenocarcinoma between 1993 and 2013 were retrospectively reviewed. In 521 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I EEC were included. The baseline patient characteristics were analyzed with the chi-square test and Fisher's exact tests. A multivariate analysis with a Cox proportional hazard model and logistic regression were performed to identify the prognostic factors for recurrence-free survival (RFS) in FIGO stage I EEC.The median follow-up period for the included patients was 74.6 months (3.1-264.9 months). Tumor recurrence occurred in 30 patients (5.8%) with a median time span of 22.85 months (2.2-124.7 months). Only 2 factors among the conventional adverse risk factors, including myometrial invasion and histologic grade, affected tumor recurrence in stage I EEC (P = .003 and P = .003, respectively). Myometrial invasion was an independent prognostic factor for RFS in stage IA EEC via multivariate analysis (P = .005). In stage IB EEC, the histologic grade was an independent prognostic factor for RFS. The median RFS of stage IB EEC was 156.0 months in grade 1, 120.0 months in grade 2, and 105.9 months in grade 3 (P = .006).Within stage I EEC, the prognostic factors for tumor recurrence were different between stages IA and IB. Myometrial invasion comprised the prognostic factor in stage IA, whereas the histologic grade comprised the prognostic factor in stage IB.
PMID
Related Publications

Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.

Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma.

An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28538399
OWN - NLM
STAT- MEDLINE
DA  - 20170524
DCOM- 20170612
LR  - 20170612
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 21
DP  - 2017 May
TI  - Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages
      IA and IB.
PG  - e6976
LID - 10.1097/MD.0000000000006976 [doi]
AB  - Risk grouping for treatment and follow-up strategy of early stage endometrial
      cancer is confusing to apply in clinical conditions. We investigated the
      stage-based prognostic factors for tumor recurrence in stage I endometrial cancer
      with endometrioid histology (EEC).The medical records of women diagnosed with
      endometrial adenocarcinoma between 1993 and 2013 were retrospectively reviewed.
      In 521 patients with International Federation of Gynecology and Obstetrics (FIGO)
      stage I EEC were included. The baseline patient characteristics were analyzed
      with the chi-square test and Fisher's exact tests. A multivariate analysis with a
      Cox proportional hazard model and logistic regression were performed to identify 
      the prognostic factors for recurrence-free survival (RFS) in FIGO stage I EEC.The
      median follow-up period for the included patients was 74.6 months (3.1-264.9
      months). Tumor recurrence occurred in 30 patients (5.8%) with a median time span 
      of 22.85 months (2.2-124.7 months). Only 2 factors among the conventional adverse
      risk factors, including myometrial invasion and histologic grade, affected tumor 
      recurrence in stage I EEC (P = .003 and P = .003, respectively). Myometrial
      invasion was an independent prognostic factor for RFS in stage IA EEC via
      multivariate analysis (P = .005). In stage IB EEC, the histologic grade was an
      independent prognostic factor for RFS. The median RFS of stage IB EEC was 156.0
      months in grade 1, 120.0 months in grade 2, and 105.9 months in grade 3 (P =
      .006).Within stage I EEC, the prognostic factors for tumor recurrence were
      different between stages IA and IB. Myometrial invasion comprised the prognostic 
      factor in stage IA, whereas the histologic grade comprised the prognostic factor 
      in stage IB.
FAU - Han, Kyung Hee
AU  - Han KH
AD  - aDepartment of Obstetrics and Gynecology, Seoul National University Hospital
      Healthcare System Gangnam Center bDepartment of Obstetrics and Gynecology cCancer
      Research Institute, Seoul National University College of Medicine dMajor in
      Biomodulation, World Class University, Seoul National University, Seoul, Republic
      of Korea.
FAU - Kim, Hee Seung
AU  - Kim HS
FAU - Lee, Maria
AU  - Lee M
FAU - Chung, Hyun Hoon
AU  - Chung HH
FAU - Song, Yong Sang
AU  - Song YS
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Endometrioid/*diagnosis/*pathology/therapy
MH  - Disease-Free Survival
MH  - Endometrial Neoplasms/*diagnosis/*pathology/therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Logistic Models
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*diagnosis/*pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC5457879
EDAT- 2017/05/26 06:00
MHDA- 2017/06/13 06:00
CRDT- 2017/05/25 06:00
AID - 10.1097/MD.0000000000006976 [doi]
AID - 00005792-201705260-00040 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 May;96(21):e6976. doi: 10.1097/MD.0000000000006976.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>